KR20110005862A - 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도 - Google Patents

변형된 제ｉｘ인자 폴리펩티드 및 이의 용도 Download PDF

Info

Publication number
KR20110005862A
KR20110005862A KR1020107025567A KR20107025567A KR20110005862A KR 20110005862 A KR20110005862 A KR 20110005862A KR 1020107025567 A KR1020107025567 A KR 1020107025567A KR 20107025567 A KR20107025567 A KR 20107025567A KR 20110005862 A KR20110005862 A KR 20110005862A
Authority
KR
South Korea
Prior art keywords
polypeptide
fix
amino acid
glu
polypeptides
Prior art date
Application number
KR1020107025567A
Other languages
English (en)
Korean (ko)
Inventor
앨런 브룩스
존 이. 머피
마리안 세토
샤오챠오 지앙
찬드라 파텔
우베 그리찬
코르넬리아 키르흐너
울리히 하우프츠
Original Assignee
바이엘 헬스케어 엘엘씨
바이엘 쉐링 파마 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 헬스케어 엘엘씨, 바이엘 쉐링 파마 악티엔게젤샤프트 filed Critical 바이엘 헬스케어 엘엘씨
Publication of KR20110005862A publication Critical patent/KR20110005862A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020107025567A 2008-04-16 2009-04-16 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도 KR20110005862A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12456708P 2008-04-16 2008-04-16
US61/124,567 2008-04-16
US4596108P 2008-04-17 2008-04-17
US61/045,961 2008-04-17

Publications (1)

Publication Number Publication Date
KR20110005862A true KR20110005862A (ko) 2011-01-19

Family

ID=41265284

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107025567A KR20110005862A (ko) 2008-04-16 2009-04-16 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도

Country Status (17)

Country Link
EP (1) EP2288622A4 (es)
JP (1) JP2011517951A (es)
KR (1) KR20110005862A (es)
CN (1) CN102083856A (es)
AU (1) AU2009244633A1 (es)
BR (1) BRPI0910702A2 (es)
CA (1) CA2721683A1 (es)
CO (1) CO6311000A2 (es)
CR (1) CR11737A (es)
DO (1) DOP2010000311A (es)
EC (1) ECSP10010551A (es)
IL (1) IL208718A0 (es)
MX (1) MX2010011345A (es)
RU (1) RU2010146387A (es)
SG (1) SG189790A1 (es)
SV (1) SV2010003704A (es)
WO (1) WO2009137254A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
JP5613876B2 (ja) * 2007-10-15 2014-10-29 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 延長された半減期を備えるヒト第ｉｘ因子変異体
DK2337849T3 (en) * 2008-09-15 2018-10-01 Uniqure Biopharma B V FACTOR IX POLYPEPTIME MUTANT, APPLICATIONS THEREOF AND METHOD OF PRODUCING THEREOF
EP2590668A4 (en) 2010-07-09 2014-04-02 Biogen Idec Hemophilia Inc FACTOR IX POLYPEPTIDES AND METHOD OF USE THEREOF
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
EP2717898B1 (en) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
EP2842966B1 (en) * 2012-04-27 2018-08-15 Nihon University Therapeutic agent for epithelial and endothelial injury
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US20150252345A1 (en) 2012-09-25 2015-09-10 Biogen Idec Ma Inc. Methods of Using FIX Polypeptides
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
PT3889173T (pt) 2013-02-15 2023-10-10 Bioverativ Therapeutics Inc Gene do fator viii otimizado
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
CN108472337B (zh) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 因子ix融合蛋白以及其制备和使用方法
RS63548B1 (sr) 2016-02-01 2022-09-30 Bioverativ Therapeutics Inc Optimizovani geni faktora viii
CN105695616A (zh) * 2016-04-22 2016-06-22 王冬国 诊断甲状腺癌的分析标志物及其应用
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
JP2020505424A (ja) 2017-01-31 2020-02-20 バイオベラティブ セラピューティクス インコーポレイテッド 因子ｉｘ融合タンパク質ならびにその製造および使用方法
FR3069540B1 (fr) 2017-07-28 2019-09-13 Universite Claude Bernard Lyon 1 Proteine modifiee avec demi-vie amelioree
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
WO2019067766A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. METHODS, COMPOSITIONS AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
CN112203646A (zh) 2018-04-04 2021-01-08 西吉隆医疗股份有限公司 可植入颗粒和相关方法
CN113227385A (zh) 2018-08-09 2021-08-06 比奥维拉迪维治疗股份有限公司 核酸分子及其用于非病毒基因疗法的用途
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
CN114008069A (zh) 2019-04-17 2022-02-01 科迪亚克生物科学公司 外来体和aav的组合物
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
CA3209399A1 (en) 2021-02-24 2022-09-01 Michael Thomas Pace System and method for a digitally beamformed phased array feed
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US6531298B2 (en) * 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
JP2005501547A (ja) * 2001-09-04 2005-01-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 修飾された第ｉｘ因子
AU2004229427A1 (en) * 2003-04-09 2004-10-28 Nektar Therapeutics Hemophilia treatment by inhalation of coagulation factors
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
MXPA06006023A (es) * 2003-12-03 2006-08-23 Neose Technologies Inc Factor ix glicopegilado.
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
BRPI0910702A2 (pt) 2016-07-05
SV2010003704A (es) 2011-02-21
WO2009137254A3 (en) 2010-01-14
SG189790A1 (en) 2013-05-31
WO2009137254A2 (en) 2009-11-12
EP2288622A4 (en) 2012-04-18
CN102083856A (zh) 2011-06-01
IL208718A0 (en) 2010-12-30
CR11737A (es) 2011-02-07
CA2721683A1 (en) 2009-11-12
EP2288622A2 (en) 2011-03-02
ECSP10010551A (es) 2010-11-30
RU2010146387A (ru) 2012-05-27
AU2009244633A1 (en) 2009-11-12
JP2011517951A (ja) 2011-06-23
CO6311000A2 (es) 2011-08-22
DOP2010000311A (es) 2011-02-28
MX2010011345A (es) 2011-02-23

Similar Documents

Publication Publication Date Title
KR20110005862A (ko) 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도
TWI595004B (zh) 經修飾之第九因子多胜肽及其用途
JP5659312B1 (ja) 改変された第ｖｉｉ因子ポリペプチドおよびその使用
ES2704083T3 (es) Polipéptidos de factor x modificados y usos de los mismos
EP1991255B1 (en) Coagulation factor x polypeptides with modified activation properties
EP3222287A1 (en) Coagulation factor ix compositions and methods of making and using same
EP2108045B1 (en) Improved fix-mutant proteins for hemophilia b treatment
EP1728798A1 (en) Coagulation factor X polypeptides with modified activation properties
KR20110015551A (ko) 제ｉｘ인자의 부위-지정 변형
SG178119A1 (en) Modified factor ix polypeptides and uses thereof
EP2108046B1 (en) Fviii-independent fix-mutant proteins for hemophilia a treatment
US20120178693A1 (en) Cofactors for Thrombin Activation of Factor VII and Uses Thereof

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application